Analyst consensus rating
ADMA Biologics Analyst Rating: Buy
ADMA is rated Buy by 5 analysts with a $17.00 target. As of 2026-08-21.
Direct answer
ADMA Biologics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked August 21, 2026.
Get free ADMA Biologics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.76
- Average price target
- $17.00
- High price target
- $21.00
- Low price target
- $12.00
- Low target gap
- +23%
- Target upside
- +74.2%
- High target gap
- +115.2%
- Target range width
- 92.2%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ADMA Biologics?
ADMA Biologics has a verified Buy consensus. The same dataset has an average price target of $17.00.
How far are ADMA Biologics's low and high targets from the recorded price?
The low target implies +23%, while the high target implies +115.2%.
How many analysts are included in ADMA Biologics's consensus?
The verified consensus includes 5 analysts.
How is ADMA Biologics's target upside or downside calculated?
The average target of $17.00 is divided by the recorded price of $9.76, then one is subtracted to produce +74.2%. This does not guarantee a future return.
When was ADMA Biologics's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.